Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Conditions

• Branch Retinal Vein Occlusion with Macular Edema

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Aflibercept Injection [Eylea] — DRUG
  Intravitreal injection is given as described in the arm description
• Ranibizumab Injection [Lucentis] — DRUG
  Intravitreal injection is given as described in the arm description

Study Details

Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.

Key Dates

Start date

Oct 18, 2018

Status verified

Oct 2024

Primary completion

Oct 15, 2021

Completion

Jul 10, 2022

Study Design

Enrollment

110 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Aflibercept
  Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
• Active Comparator: Ranibizumab
  Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.

Primary Outcome Measure

Difference in time to recurrence of macular edema [ Time Frame: 9 months ]